Table 2 Stage 1 and 2 patients without MYCNA. Characteristics at diagnosis
Stage | |||||||
|---|---|---|---|---|---|---|---|
1 ( n =288) | 2 ( n =123) | ||||||
Characteristics | No. of patients | % | 95% CI | No. of patients | % | 95% CI | P -value |
Gender | |||||||
Male | 167 | 58 | 52.3–63.7 | 61 | 49.6 | 40.8–58.4 | 0.11 |
Female | 121 | 42 | 36.3–47.7 | 62 | 50.4 | 41.6–59.2 | |
M/F ratio | 1.4 | 1 | |||||
Age (months) | 0.63 | ||||||
Median | 11 | 11 | |||||
0–17 | 185 | 64.2 | 58.7–69.8 | 76 | 61.8 | 53.2–70.4 | |
>18 | 103 | 35.8 | 30.2–41.3 | 47 | 38.2 | 29.6–46.8 | |
Site of primary tumour | <0.0025 | ||||||
Neck | 14 | 4.9 | 2.4–7.3 | 7 | 5.7 | 2.3–11.4 | |
Thorax | 65 | 22.5 | 17.7–27.4 | 43 | 35 | 26.5–43.4 | |
Abdomen | 197 | 68.4 | 63–73.8 | 61 | 49.6 | 40.8–58.4 | |
Pelvis | 12 | 4.2 | 1.9–6.5 | 12 | 9.7 | 4.5–15 | |
Urine VMA (247 tested) | 0.0008 | ||||||
Normal | 118 | 67.4 | 60.5–74.4 | 32 | 44.4 | 33–55.9 | |
Elevated | 57 | 32.6 | 25.6–39.5 | 40 | 55.6 | 44.1–67 | |
Urine HVA (231tested) | 0.015 | ||||||
Normal | 108 | 67.5 | 60.2–74.8 | 36 | 50.7 | 39.1–62.3 | |
Elevated | 52 | 32.5 | 25.2–39.8 | 35 | 49.3 | 37.7–60.9 | |
Serum LDH (276 tested) | 0.79 | ||||||
Normal | 161 | 93.1 | 89.3–96.8 | 95 | 92.2 | 85.3–96.6 | |
Elevated | 12 | 6.9 | 3.1–10.7 | 8 | 7.8 | 3.4–14.7 | |
Histopathologic category (320 tested) | <0.04 | ||||||
Favourable | 191 | 88.4 | 84.2–92.7 | 83 | 79.8 | 72.1–87.5 | |
Unfavourable | 25 | 11.6 | 7.3–15.8 | 21 | 20.2 | 12.5–27.9 | |
DNA index (216 tested) | 0.72 | ||||||
Aneuploid | 90 | 64.3 | 56.3–72.2 | 47 | 61.8 | 50.9–72.8 | |
Di-tetraploid | 50 | 35.7 | 27.8–43.6 | 29 | 38.2 | 27.2–49.1 | |
